ABT vs AM · P/E 25, rev $44.33B vs P/E 25, rev $1.11B
Abbott Laboratories (ABT) versus Antero Midstream Partners LP (AM) — a side-by-side from cached financials, not a winner call.
Abbott Laboratories (ABT) is a medical devices company listed on NYSE.
Antero Midstream Partners LP (AM) is a oil & gas midstream company listed on NYSE.
Latest reported ABT revenue for 2025-12-31 was $44.33B. Net income was $6.52B. Revenue was up 5.7% from 2024-12-31 to 2025-12-31. ABT currently screens at market cap $154.15B and trailing P/E 24.8.
Latest reported AM revenue for 2024-12-31 was $1.11B. Net income was $400.9M. Revenue was up 6.2% from 2023-12-31 to 2024-12-31. AM currently screens at market cap $10.19B and trailing P/E 24.9.
ABT currently screens at market cap $154.15B and trailing P/E 24.8. AM currently screens at market cap $10.19B and trailing P/E 24.9.
Not investment advice. Open the ABT and AM stock pages for the full models.
Not investment advice.